Etanercept

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)2.93 [1.53, 5.60]5%7 studies34238not evaluable ROB5.30 [2.43; .]
Major congenital malformations2.61 [1.40, 4.86]0%6 studies31232not evaluable ROB4.66 [2.15; .]
Congenital heart defects--0 study-
Digestive system anomalies--0 study-
Ear malformations--0 study-
Eye defects--0 study-
Limb defects--0 study-
Nervous system anomalies--0 study-
Oro-facial clefts--0 study-
Respiratory system anomalies--0 study-

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)1.50 [1.10, 2.04]0%5 studies323249not evaluable ROB2.37 [1.44; .]
Small for gestational age (weight)4.36 [0.71, 26.61]0%2 studies615not evaluable ROB-
Low birth weight (< 2500g)1.71 [1.14, 2.58]-1 study203217not evaluable ROB2.82 [1.53; .]
1 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Caesarean--0 study-
Preeclampsia0.67 [0.02, 19.22]76%2 studies11104not evaluable ROB-
2 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Neonatal infections1.82 [0.83, 3.97]0%2 studies58204not evaluable ROB-
Low Apgar score (< 7) (at 5 min)--0 study-
1 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Early intrauterine death (< 22 weeks)0.66 [0.30, 1.45]73%5 studies622832not evaluable ROB-
Elective/induced termination of pregnancy1.03 [0.70, 1.52]0%3 studies293367not evaluable ROB-
Late intrauterine deaths (> 22 weeks)0.82 [0.22, 3.09]0%2 studies28350not evaluable ROB-
2 non statistically significant endpoints reported in only one study